Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Tuberculosis

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 187 articles:
HTML format
Text format



Single Articles


    February 2018
  1. SULIS G, Agliati A, Pinsi G, Bozzola G, et al
    Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting.
    Eur Respir J. 2018 Feb 8. pii: 13993003.02345-2017.
    PubMed     Text format    


  2. AKKERMAN OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, et al
    Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.
    Eur Respir J. 2018 Feb 1. pii: 13993003.02490-2017.
    PubMed     Text format    


  3. CHIANG CY, Trebucq A
    Tuberculosis re-treatment after exclusion of rifampicin resistance.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  4. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
    A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  5. JOHNSTON JC, van der Kop ML, Smillie K, Ogilvie G, et al
    The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


    January 2018
  6. HEYSELL SK, Ahmed S, Rahman MT, Akhanda MW, et al
    Hearing loss with Kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh.
    Eur Respir J. 2018 Jan 18. pii: 13993003.01778-2017.
    PubMed     Text format    


  7. ACUNA-VILLAORDUNA C, Jones-Lopez EC, Fregona G, Marques-Rodrigues P, et al
    Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  8. NGWATU BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, et al
    The impact of digital health technologies on tuberculosis treatment: a systematic review.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  9. LOUTET MG, Burman M, Jayasekera N, Trathen D, et al
    National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  10. AL YAQUOBI F, Al-Abri S, Al-Abri B, Al-Abaidani I, et al
    Tuberculosis elimination: a dream or a reality? The case of Oman.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  11. VAN DEN ELSEN SHJ, Akkerman OW, Huisman JR, Touw DJ, et al
    Lack of penetration of amikacin into saliva of tuberculosis patients.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  12. PADRAO E, Oliveira O, Felgueiras O, Gaio AR, et al
    Tuberculosis and tobacco: is there any epidemiological association?
    Eur Respir J. 2018;51.
    PubMed     Text format    


    December 2017
  13. CHE Y, Song Q, Yang T, Ping G, et al
    Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  14. CABIBBE AM, Sotgiu G, Izco S, Migliori GB, et al
    Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  15. ABADIE ME, Strich JR, Kim T, Xie YL, et al
    Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  16. MIOTTO P, Tessema B, Tagliani E, Chindelevitch L, et al
    A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


    November 2017
  17. LUZZATI R, Migliori GB, Zignol M, Cirillo DM, et al
    Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  18. FALZON D, Migliori GB, Jaramillo E, Weyer K, et al
    Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  19. FURIN J, Lessem E, Cox V
    Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  20. KUKSA L, Barkane L, Hittel N, Gupta R, et al
    Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  21. VAN DER WERF MJ, Sotgiu G, Dara M
    Closing the gap in surveillance of tuberculosis and HIV co-infection: a European perspective on the need for clinician-public health alliances.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  22. ARNOLDUSSEN M, Schimmel H, Op de Coul E, van den Hof S, et al
    Tuberculosis patients with unknown HIV status in the Netherlands: analysing underreporting and lack of testing.
    Eur Respir J. 2017;50.
    PubMed     Text format    


    October 2017
  23. VAN DE BERG S, Erkens C, van Rest J, van den Hof S, et al
    Evaluation of tuberculosis screening of immigrants in the Netherlands.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  24. HELDAL E
    A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  25. CHESOV D, Ciobanu N, Lange C, Heyckendorf J, et al
    High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  26. KODAMA C, Lange B, Olaru ID, Khan P, et al
    Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  27. FIEBIG L, Hauer B, Andres M, Haas W, et al
    Tuberculosis screening in asylum seekers in Germany, 2015: characteristics of cases and yield.
    Eur Respir J. 2017;50.
    PubMed     Text format    


    September 2017
  28. FOURNIER A, Bernard C, Sougakoff W, Quelet S, et al
    Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission.
    Eur Respir J. 2017;50.
    PubMed     Text format    


    August 2017
  29. CHEE CBE, KhinMar KW, Sng LH, Jureen R, et al
    The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
    Eur Respir J. 2017;50.
    PubMed     Text format    


  30. CAZABON D, Suresh A, Oghor C, Qin ZZ, et al
    Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?
    Eur Respir J. 2017;50.
    PubMed     Text format    


  31. LEE MR, Ho CM, Lee CH, Lee MC, et al
    Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  32. DOBLER CC, Cheung K, Nguyen J, Martin A, et al
    Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


    July 2017
  33. CAMINERO JA, Piubello A, Scardigli A, Migliori GB, et al
    Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  34. AHMAD KHAN F, Pande T, Tessema B, Song R, et al
    Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  35. RAVIGLIONE M, Poznyak V
    Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  36. IMTIAZ S, Shield KD, Roerecke M, Samokhvalov AV, et al
    Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  37. AHMAD KHAN F, Salim MAH, du Cros P, Casas EC, et al
    Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  38. ZENNER D, Loutet MG, Harris R, Wilson S, et al
    Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  39. GUGLIELMETTI L, Varaine F, Huerga H, Bonnet M, et al
    Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  40. ONI T, Berkowitz N, Kubjane M, Goliath R, et al
    Trilateral overlap of tuberculosis, diabetes and HIV-1 in a high-burden African setting: implications for TB control.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  41. MULLERPATTAN JB, Nikam C, Sharma U, Rodrigues C, et al
    Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India?
    Eur Respir J. 2017;50.
    PubMed     Text format    


    June 2017
  42. SOLOVIC I, Abubakar I, Sotgiu G, Dara M, et al
    Standard operating procedures for tuberculosis care.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  43. VAN DER WERF MJ, Kodmon C, Catchpole M
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  44. HELDAL E, Van Deun A, Chiang CY, Rieder HL, et al
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  45. VAN DEUN A, Chiang CY
    Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  46. BOERE TM, Visser DH, van Furth AM, Lips P, et al
    Solar ultraviolet B exposure and global variation in tuberculosis incidence: an ecological analysis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    May 2017
  47. OLARU ID, Heyckendorf J, Andres S, Kalsdorf B, et al
    Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  48. GUGLIELMETTI L
    Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
    Eur Respir J. 2017;49.
    PubMed     Text format    


  49. MILLER C, Lonnroth K, Sotgiu G, Migliori GB, et al
    The long and winding road of chest radiography for tuberculosis detection.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  50. RAHMAN MT, Codlin AJ, Rahman MM, Nahar A, et al
    An evaluation of automated chest radiography reading software for tuberculosis screening among public- and private-sector patients.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    April 2017
  51. CATANZARO DG, Trollip AP, Seifert M, Georghiou SB, et al
    Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  52. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  53. NAKIWALA D, Kellgren L, Herzmann C, Olaru ID, et al
    Language discordance between tuberculosis patients and healthcare providers challenging universal access.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  54. BOZORGMEHR K, Joggerst B, Wagner U, Stock C, et al
    Yield of tuberculosis screening in asylum-seekers by country of origin: analysis of screening data in a German federal state (2002-2015).
    Eur Respir J. 2017;49.
    PubMed     Text format    


  55. FALZON D, Jaramillo E, Gilpin C, Weyer K, et al
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  56. DAVIES FORSMAN L, Bruchfeld J, Alffenaar JC
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    March 2017
  57. PONTALI E, D'Ambrosio L, Centis R, Sotgiu G, et al
    Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  58. YASSIN MA, Jaramillo E, Wandwalo E, Falzon D, et al
    Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  59. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  60. FALZON D, Schunemann HJ, Harausz E, Gonzalez-Angulo L, et al
    World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  61. SINKOU H, Hurevich H, Rusovich V, Zhylevich L, et al
    Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  62. VAN DER WERF MJ, Hollo V, Kodmon C, Dara M, et al
    Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  63. KAMADA A, Amishima M
    QuantiFERON-TB(R) Gold Plus as a potential tuberculosis treatment monitoring tool.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  64. BJORN-MORTENSEN K, Lillebaek T, Koch A, Soborg B, et al
    Extent of transmission captured by contact tracing in a tuberculosis high endemic setting.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  65. VAN KAMPENHOUT E, Bolhuis MS, Alffenaar JC, Oswald LM, et al
    Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  66. UDWADIA ZF, Ganatra S, Mullerpattan JB
    Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  67. GARCIA-BASTEIRO AL, Miranda Ribeiro R, Brew J, Sacoor C, et al
    Tuberculosis on the rise in southern Mozambique (1997-2012).
    Eur Respir J. 2017;49.
    PubMed     Text format    


  68. VAN DER PAARDT AL, Akkerman OW, Gualano G, Palmieri F, et al
    Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  69. LU P, Liu Q, Martinez L, Yang H, et al
    Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  70. ROTH DZ, Ronald LA, Ling D, Chiang LY, et al
    Impact of interferon-gamma release assay on the latent tuberculosis cascade of care: a population-based study.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  71. BASTOS ML, Lan Z, Menzies D
    An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    February 2017
  72. BLASI F, Matteelli A, Sotgiu G, Cirillo DM, et al
    Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    January 2017
  73. SOTGIU G, Migliori GB
    Group 5 drugs for multidrug-resistant tuberculosis: is the glass half full or half empty?
    Eur Respir J. 2017;49.
    PubMed     Text format    


  74. JAVAID A, Ahmad N, Khan AH, Shaheen Z, et al
    Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  75. FOX GJ, Benedetti A, Cox H, Koh WJ, et al
    Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  76. IZCO S, Eyene J, Perez-Lago L, Herranz M, et al
    Equatorial Guinea, a multidrug-resistant tuberculosis hotspot in Central Africa.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  77. FRANCISCO J, Oliveira O, Felgueiras O, Gaio AR, et al
    How much is too much alcohol in tuberculosis?
    Eur Respir J. 2017;49.
    PubMed     Text format    


  78. NATHAVITHARANA RR, Cudahy PG, Schumacher SG, Steingart KR, et al
    Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available



  79. "Monitoring latent tuberculosis infection diagnosis and management in the Netherlands." Connie G.M. Erkens, Erika Slump, Maurits Verhagen, Henrieke Schimmel, Gerard de Vries, Frank Cobelens and Susan van den Hof. Eur Respir J 2016; 47: 1492-1501.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  80. LIENHARDT C, Nahid P, Rich ML, Bansbach C, et al
    Target regimen profiles for treatment of tuberculosis: a WHO document.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    December 2016
  81. PEDRAZZOLI D, Lalli M, Boccia D, Houben R, et al
    Can tuberculosis patients in resource-constrained settings afford chest radiography?
    Eur Respir J. 2016 Dec 23. pii: 1601877. doi: 10.1183/13993003.01877-2016.
    PubMed     Text format    


  82. GUGLIELMETTI L, Jaspard M, Le Du D, Lachatre M, et al
    Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Dec 22. pii: 1601799. doi: 10.1183/13993003.01799-2016.
    PubMed     Text format     Abstract available


  83. VEZIRIS N, Bernard C, Guglielmetti L, Le Du D, et al
    Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
    Eur Respir J. 2016 Dec 22. pii: 1601719. doi: 10.1183/13993003.01719-2016.
    PubMed     Text format    


    November 2016
  84. PETRUCCIOLI E, Scriba TJ, Petrone L, Hatherill M, et al
    Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis.
    Eur Respir J. 2016 Nov 11. pii: ERJ-01012-2016. doi: 10.1183/13993003.01012-2016
    PubMed     Text format     Abstract available


  85. ALBERT H, Nathavitharana RR, Denkinger CM, Isaacs C, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1531-1532.
    PubMed     Text format    


  86. MASON PH, Oni T, van Herpen MM, Coussens AK, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1529-1531.
    PubMed     Text format    


  87. TADOLINI M, Lingtsang RD, Tiberi S, Enwerem M, et al
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1527-1529.
    PubMed     Text format    


  88. WALLIS RS
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1526-1527.
    PubMed     Text format    


  89. PILARSKI A, Penn N, Ratnakumar S, Barker RD, et al
    Variation in vitamin D deficiency among tuberculosis patients by ethnic group and geographical region of birth: evidence from a diverse south London population.
    Eur Respir J. 2016;48:1507-1510.
    PubMed     Text format    


  90. ERKENS CG, Slump E, Verhagen M, Schimmel H, et al
    Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands.
    Eur Respir J. 2016;48:1420-1428.
    PubMed     Text format     Abstract available


  91. RENDON A, Fuentes Z, Torres-Duque CA, Granado MD, et al
    Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance.
    Eur Respir J. 2016;48:1282-1287.
    PubMed     Text format    


  92. SOTGIU G, Beer N, Aliberti S, Migliori GB, et al
    Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care.
    Eur Respir J. 2016;48:1278-1281.
    PubMed     Text format    


    October 2016
  93. UPLEKAR M, Atre S, Wells WA, Weil D, et al
    Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice.
    Eur Respir J. 2016 Oct 20. pii: ERJ-00956-2016. doi: 10.1183/13993003.00956-2016
    PubMed     Text format     Abstract available


  94. VAN ALTENA R, Akkerman OW, Alffenaar JC, Kerstjens HA, et al
    Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.
    Eur Respir J. 2016 Oct 6. pii: ERJ-01208-2016. doi: 10.1183/13993003.01208-2016.
    PubMed     Text format    


  95. LEE RS, Proulx JF, Menzies D, Behr MA, et al
    Progression to tuberculosis disease increases with multiple exposures.
    Eur Respir J. 2016 Oct 6. pii: ERJ-00893-2016. doi: 10.1183/13993003.00893-2016.
    PubMed     Text format     Abstract available


  96. DE VRIES G, van Rest J, Meijer W, Schimmel H, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1255-1256.
    PubMed     Text format    


  97. ARRAZOLA DE ONATE W, Weber L, Janssens K, Wanlin M, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1253-1254.
    PubMed     Text format    


    September 2016
  98. WINGFIELD T, Tovar MA, Huff D, Boccia D, et al
    The economic effects of supporting tuberculosis-affected households in Peru.
    Eur Respir J. 2016 Sep 22. pii: ERJ-00066-2016. doi: 10.1183/13993003.00066-2016
    PubMed     Text format     Abstract available


  99. SOTGIU G, Pontali E, Centis R, D'Ambrosio L, et al
    New anti-tuberculosis drugs for special populations: a difficult-to-address issue.
    Eur Respir J. 2016;48:957-8.
    PubMed     Text format    


  100. ZUUR MA, Akkerman OW, Davies Forsman L, Hu Y, et al
    Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?
    Eur Respir J. 2016 Sep 1. pii: ERJ-00833-2016. doi: 10.1183/13993003.00833-2016.
    PubMed     Text format    


  101. ANDERSON C, Anderson SR, Maguire H, Hayward AC, et al
    Tuberculosis in London: the convergence of clinical and social complexity.
    Eur Respir J. 2016 Sep 1. pii: ERJ-00749-2016. doi: 10.1183/13993003.00749-2016.
    PubMed     Text format    


  102. MITNICK CD, White RA, Lu C, Rodriguez CA, et al
    Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.
    Eur Respir J. 2016 Sep 1. pii: ERJ-00462-2016. doi: 10.1183/13993003.00462-2016.
    PubMed     Text format     Abstract available


  103. SOTGIU G, Nahid P, Loddenkemper R, Abubakar I, et al
    The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis.
    Eur Respir J. 2016 Sep 1. pii: ERJ-01356-2016. doi: 10.1183/13993003.01356-2016.
    PubMed     Text format    


  104. SOTGIU G, Tiberi S, D'Ambrosio L, Centis R, et al
    Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Sep 1. pii: ERJ-01249-2016. doi: 10.1183/13993003.01249-2016.
    PubMed     Text format    


  105. SMIRNOVA PA, Turkova A, Nikishova EI, Seddon JA, et al
    Multidrug-resistant tuberculosis in children in northwest Russia: an observational cohort study.
    Eur Respir J. 2016 Sep 1. pii: ERJ-00354-2016. doi: 10.1183/13993003.00354-2016.
    PubMed     Text format    


    August 2016
  106. STURKENBOOM MG, Akkerman OW, van Altena R, de Lange WC, et al
    Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.
    Eur Respir J. 2016 Aug 4. pii: ERJ-00986-2016. doi: 10.1183/13993003.00986-2016.
    PubMed     Text format    


  107. DARA M, Solovic I, Sotgiu G, D'Ambrosio L, et al
    Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices.
    Eur Respir J. 2016 Aug 4. pii: ERJ-00840-2016. doi: 10.1183/13993003.00840-2016.
    PubMed     Text format     Abstract available


    July 2016
  108. BLOK N, van den Boom M, Erkens C, Dara M, et al
    Variation in policy and practice of adolescent tuberculosis management in the WHO European Region.
    Eur Respir J. 2016 Jul 28. pii: ERJ-00704-2016. doi: 10.1183/13993003.00704-2016
    PubMed     Text format    


  109. ALBERT H, Nathavitharana RR, Isaacs C, Pai M, et al
    Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?
    Eur Respir J. 2016 Jul 13. pii: ERJ-00543-2016. doi: 10.1183/13993003.00543-2016
    PubMed     Text format     Abstract available


  110. MARX FM, Floyd S, Ayles H, Godfrey-Faussett P, et al
    High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions.
    Eur Respir J. 2016 Jul 7. pii: ERJ-00716-2016. doi: 10.1183/13993003.00716-2016.
    PubMed     Text format    



  111. ERJ July Podcast: tuberculosis prevention and control in refugees.
    Eur Respir J. 2016;48:E67.
    PubMed     Text format    


  112. DE VRIES G, van Rest J, Meijer W, Wolters B, et al
    Preventing and controlling tuberculosis among refugees in Europe: more needed for high-risk populations.
    Eur Respir J. 2016;48:274-6.
    PubMed     Text format    


  113. DARA M, Solovic I, Goletti D, Sotgiu G, et al
    Preventing and controlling tuberculosis among refugees in Europe: more is needed.
    Eur Respir J. 2016;48:272-4.
    PubMed     Text format    


    June 2016
  114. TADOLINI M, Garcia-Prats AJ, D'Ambrosio L, Hewison C, et al
    Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.
    Eur Respir J. 2016 Jun 23. pii: ERJ-00705-2016. doi: 10.1183/13993003.00705-2016
    PubMed     Text format    


  115. GUGLIELMETTI L, Le Du D, Veziris N, Caumes E, et al
    Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
    Eur Respir J. 2016 Jun 23. pii: ERJ-00411-2016. doi: 10.1183/13993003.00411-2016
    PubMed     Text format    


  116. TADOLINI M, Lingtsang RD, Tiberi S, Enwerem M, et al
    First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Eur Respir J. 2016 Jun 10. pii: ERJ-00637-2016. doi: 10.1183/13993003.00637-2016
    PubMed     Text format    


  117. ZUUR MA, Akkerman OW, Touw DJ, van der Werf TS, et al
    Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV.
    Eur Respir J. 2016 Jun 10. pii: ERJ-00599-2016. doi: 10.1183/13993003.00599-2016
    PubMed     Text format    


  118. EDWARDS TL, Valverde E, Mulder C, Cox C, et al
    Pouched rats as detectors of tuberculosis: comparison to concentrated smear microscopy.
    Eur Respir J. 2016 Jun 10. pii: ERJ-00264-2016. doi: 10.1183/13993003.00264-2016
    PubMed     Text format    


    May 2016
  119. GAO L, Bai L, Liu J, Lu W, et al
    Annual risk of tuberculosis infection in rural China: a population-based prospective study.
    Eur Respir J. 2016 May 26. pii: ERJ-00235-2016. doi: 10.1183/13993003.00235-2016
    PubMed     Text format     Abstract available


  120. CORDEIRO DA COSTA J, Oliveira O, Baia L, Gaio R, et al
    Prevalence and factors associated with diabetes mellitus among tuberculosis patients: a nationwide cohort.
    Eur Respir J. 2016 May 12. pii: ERJ-00254-2016. doi: 10.1183/13993003.00254-2016
    PubMed     Text format    


  121. DOBLER CC, Martin A, Marks GB
    Benefit of treatment of latent tuberculosis infection in individual patients.
    Eur Respir J. 2016;47:1594-5.
    PubMed     Text format    


  122. FLUEGGE K
    Benefit of treatment of latent tuberculosis infection in individual patients.
    Eur Respir J. 2016;47:1592-4.
    PubMed     Text format    


  123. GETAHUN H, Matteelli A, Abubakar I, Hauer B, et al
    Advancing global programmatic management of latent tuberculosis infection for at risk populations.
    Eur Respir J. 2016;47:1327-30.
    PubMed     Text format    


    April 2016
  124. VAN HEST R, de Vries G
    Active tuberculosis case-finding among drug users and homeless persons: after the outbreak.
    Eur Respir J. 2016 Apr 21. pii: ERJ-00284-2016. doi: 10.1183/13993003.00284-2016
    PubMed     Text format    


  125. BLANKLEY S, Graham CM, Levin J, Turner J, et al
    A 380-gene meta-signature of active tuberculosis compared with healthy controls.
    Eur Respir J. 2016 Apr 13. pii: ERJ-02121-2015. doi: 10.1183/13993003.02121-2015
    PubMed     Text format    


  126. BOLHUIS MS, Tiberi S, Sotgiu G, De Lorenzo S, et al
    Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?
    Eur Respir J. 2016;47:1288-90.
    PubMed     Text format    


  127. CATTANEO D, Gervasoni C, Clementi E
    Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?
    Eur Respir J. 2016;47:1287-8.
    PubMed     Text format    


  128. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Eur Respir J. 2016;47:1235-43.
    PubMed     Text format     Abstract available


    March 2016
  129. AKKERMAN OW, de Lange WC, Scholvinck EH, Wolters B, et al
    Implementing tuberculosis entry screening for asylum seekers: the Groningen experience.
    Eur Respir J. 2016 Mar 23. pii: ERJ-00112-2016. doi: 10.1183/13993003.00112-2016
    PubMed     Text format    


  130. DARA M, Solovic I, Sotgiu G, D'Ambrosio L, et al
    Statement of the European Respiratory Society and the European Region of the International Union Against Tuberculosis and Lung Disease: call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees.
    Eur Respir J. 2016 Mar 23. pii: ERJ-00377-2016. doi: 10.1183/13993003.00377-2016
    PubMed     Text format    


  131. GHIMIRE S, Bolhuis MS, Sturkenboom MG, Akkerman OW, et al
    Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics.
    Eur Respir J. 2016 Mar 17. pii: ERJ-00040-2016. doi: 10.1183/13993003.00040-2016
    PubMed     Text format    


  132. DE VRIES G, van Rest J, Meijer W, Wolters B, et al
    Low yield of screening asylum seekers from countries with a tuberculosis incidence of <50 per 100 000 population.
    Eur Respir J. 2016 Mar 10. pii: ERJ-00099-2016. doi: 10.1183/13993003.00099-2016
    PubMed     Text format    


  133. PAI M, Sotgiu G
    Diagnostics for latent TB infection: incremental, not transformative progress.
    Eur Respir J. 2016;47:704-6.
    PubMed     Text format    


  134. KOLAHIAN S, Oz HH, Zhou B, Griessinger CM, et al
    The emerging role of myeloid-derived suppressor cells in lung diseases.
    Eur Respir J. 2016;47:967-77.
    PubMed     Text format     Abstract available


    February 2016
  135. ERKENS CG, Slump E, Verhagen M, Schimmel H, et al
    Monitoring latent tuberculosis infection diagnosis and management in the Netherlands.
    Eur Respir J. 2016 Feb 25. pii: ERJ-01397-2015. doi: 10.1183/13993003.01397-2015
    PubMed     Text format     Abstract available


  136. PANG Y, Du J, Qin ZZ, Greenwald Z, et al
    An overview on tuberculosis-specific hospitals in China in 2009: results of a national survey.
    Eur Respir J. 2016 Feb 25. pii: ERJ-01854-2015. doi: 10.1183/13993003.01854-2015
    PubMed     Text format    


  137. FATTORINI L, Mustazzolu A, Borroni E, Piccaro G, et al
    Tuberculosis in migrants from 106 countries in Italy, 2008-2014.
    Eur Respir J. 2016 Feb 4. pii: ERJ-01844-2015. doi: 10.1183/13993003.01844-2015.
    PubMed     Text format    


  138. VENKATRAMAN N, King T, Bell D, Woltmann G, et al
    High levels of neurological involvement but low mortality in miliary tuberculosis: a 6-year case-series from the UK.
    Eur Respir J. 2016 Feb 4. pii: ERJ-01958-2015. doi: 10.1183/13993003.01958-2015.
    PubMed     Text format    


  139. MATTEELLI A, Lonnroth K, Mosca D, Getahun H, et al
    Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration.
    Eur Respir J. 2016;47:686-8.
    PubMed     Text format    


  140. PONTALI E, Sotgiu G, D'Ambrosio L, Centis R, et al
    Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence.
    Eur Respir J. 2016;47:394-402.
    PubMed     Text format    


  141. NOESKE J, Foe JL, Kuaban C
    Cameroon's MDR-TB treatment programme jeopardised by cross-border migration.
    Eur Respir J. 2016;47:684-6.
    PubMed     Text format    


  142. VAN DER BURGT EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, et al
    End TB with precision treatment!
    Eur Respir J. 2016;47:680-2.
    PubMed     Text format    


    January 2016
  143. VAN RIJN SP, van Altena R, Akkerman OW, van Soolingen D, et al
    Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Jan 7. pii: ERJ-01654-2015. doi: 10.1183/13993003.01654-2015.
    PubMed     Text format     Abstract available


  144. AMARAL AF, Coton S, Kato B, Tan WC, et al
    Lung function defects in treated pulmonary tuberculosis patients.
    Eur Respir J. 2016;47:352-3.
    PubMed     Text format    


  145. AGGARWAL D, Ku V, Janmeja AK
    Lung function defects in treated pulmonary tuberculosis patients.
    Eur Respir J. 2016;47:351-2.
    PubMed     Text format    


  146. BRIGDEN G, du Cros P, Wong S
    Barriers to new drug development in respiratory disease.
    Eur Respir J. 2016;47:356-7.
    PubMed     Text format    


  147. PINETON DE CHAMBRUN M, Lemiale V, Azoulay E
    Lung positron emission tomography with FDG in patients with haematological malignancies and acute respiratory failure.
    Eur Respir J. 2016;47:324-7.
    PubMed     Text format    


    December 2015
  148. LOPEZ-VARELA E, Augusto OJ, Guerra L, Respeito D, et al
    Low paediatric tuberculosis case detection rate in Southern Mozambique.
    Eur Respir J. 2015 Dec 23. pii: ERJ-01454-2015. doi: 10.1183/13993003.01454-2015
    PubMed     Text format    


  149. HOFF ST, Peter JG, Theron G, Pascoe M, et al
    Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection.
    Eur Respir J. 2015 Dec 17. pii: ERJ-01464-2015. doi: 10.1183/13993003.01464-2015
    PubMed     Text format     Abstract available


  150. DIEL R, Nienhaus A, Hillemann D, Richter E, et al
    Cost-benefit analysis of Xpert(R) MTB/RIF for tuberculosis suspects in German hospitals.
    Eur Respir J. 2015 Dec 2. pii: ERJ-01333-2015. doi: 10.1183/13993003.01333-2015.
    PubMed     Text format     Abstract available


  151. SIWENDU S, Mitchell M, Diacon AH, von Groote-Bidlingmaier F, et al
    Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis.
    Eur Respir J. 2015 Dec 2. pii: ERJ-01330-2015. doi: 10.1183/13993003.01330-2015.
    PubMed     Text format    


  152. PYM AS, Diacon AH, Tang SJ, Conradie F, et al
    Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Eur Respir J. 2015 Dec 2. pii: ERJ-00724-2015. doi: 10.1183/13993003.00724-2015.
    PubMed     Text format     Abstract available


  153. CHANG EW, Page AL, Bonnet M
    Light-emitting diode fluorescence microscopy for tuberculosis diagnosis: a meta-analysis.
    Eur Respir J. 2015 Dec 2. pii: ERJ-00978-2015. doi: 10.1183/13993003.00978-2015.
    PubMed     Text format     Abstract available



  154. ERJ December Podcast: Management of latent Mycobacterium tuberculosis infection.
    Eur Respir J. 2015;46:E60.
    PubMed     Text format    


  155. HUGHES J, Isaakidis P, Andries A, Mansoor H, et al
    Linezolid in drug-resistant tuberculosis: haste makes waste.
    Eur Respir J. 2015;46:1844-6.
    PubMed     Text format    


  156. BHUNIYA S, Mohapatra PR, Panigrahi MK, Behera P, et al
    Linezolid in drug-resistant tuberculosis: haste makes waste.
    Eur Respir J. 2015;46:1843-4.
    PubMed     Text format    


  157. SOTGIU G, Cirillo DM, Miotto P, Centis R, et al
    Accelerating tuberculosis elimination in low-incidence settings: the role of genomics.
    Eur Respir J. 2015;46:1841-3.
    PubMed     Text format    


  158. GUTHRIE JL, Gardy JL
    Accelerating tuberculosis elimination in low-incidence settings: the role of genomics.
    Eur Respir J. 2015;46:1840-1.
    PubMed     Text format    


  159. MATTEELLI A, Lonnroth K, Getahun H, Falzon D, et al
    Numbers needed to treat to prevent tuberculosis.
    Eur Respir J. 2015;46:1838-9.
    PubMed     Text format    


  160. SESTER M, van Crevel R, Leth Fv, Lange C, et al
    Numbers needed to treat to prevent tuberculosis.
    Eur Respir J. 2015;46:1836-8.
    PubMed     Text format    


    November 2015
  161. TIBERI S, D'Ambrosio L, De Lorenzo S, Viggiani P, et al
    Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.
    Eur Respir J. 2015 Nov 19. pii: ERJ-01278-2015. doi: 10.1183/13993003.01278-2015
    PubMed     Text format    


  162. LOSI M, Knights AJ, Mariani F, Altieri AM, et al
    QuantiFERON-TB performance enhanced by novel Mycobacterium tuberculosis-specific antigens.
    Eur Respir J. 2015 Nov 19. pii: ERJ-01015-2015. doi: 10.1183/13993003.01015-2015
    PubMed     Text format    


  163. TIBERI S, D'Ambrosio L, De Lorenzo S, Viggiani P, et al
    Tuberculosis elimination, patients' lives and rational use of new drugs: revisited.
    Eur Respir J. 2015 Nov 5. pii: ERJ-01297-2015. doi: 10.1183/13993003.01297-2015.
    PubMed     Text format    


    October 2015
  164. FIEBIG L, Hauer B, Brodhun B, Altmann D, et al
    Tuberculosis in Germany: a declining trend coming to an end?
    Eur Respir J. 2015 Oct 22. pii: ERJ-01410-2015. doi: 10.1183/13993003.01410-2015
    PubMed     Text format    


  165. TOGUN TO, Egere U, Gomez MP, Sillah AK, et al
    No added value of interferon-gamma release to a prediction model for childhood tuberculosis.
    Eur Respir J. 2015 Oct 22. pii: ERJ-00890-2015. doi: 10.1183/13993003.00890-2015
    PubMed     Text format     Abstract available


  166. WOLFSON LJ, Gibbert J, Wirth D, Diel R, et al
    Cost-effectiveness of incorporating bedaquiline into a treatment regimen for multidrug-resistant/extensively drug-resistant tuberculosis in Germany.
    Eur Respir J. 2015 Oct 22. pii: ERJ-00811-2015. doi: 10.1183/13993003.00811-2015
    PubMed     Text format    


  167. TICONA E, Huaman MA, Huaroto LM, Burgos M, et al
    Tuberculosis screening using ability to provide sputum in an endemic emergency department.
    Eur Respir J. 2015 Oct 22. pii: ERJ-00877-2015. doi: 10.1183/13993003.00877-2015
    PubMed     Text format    


    September 2015
  168. DOBLER CC, Martin A, Marks GB
    Benefit of treatment of latent tuberculosis infection in individual patients.
    Eur Respir J. 2015 Sep 24. pii: ERJ-00577-2015. doi: 10.1183/13993003.00577-2015
    PubMed     Text format     Abstract available


  169. PANDE T, Pai M, Khan FA, Denkinger CM, et al
    Use of chest radiography in the 22 highest tuberculosis burden countries.
    Eur Respir J. 2015 Sep 24. pii: ERJ-01064-2015. doi: 10.1183/13993003.01064-2015
    PubMed     Text format    


  170. GETAHUN H, Matteelli A, Abubakar I, Aziz MA, et al
    Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
    Eur Respir J. 2015 Sep 24. pii: ERJ-01245-2015. doi: 10.1183/13993003.01245-2015
    PubMed     Text format     Abstract available


  171. WINTERS N, Butler-Laporte G, Menzies D
    Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.
    Eur Respir J. 2015 Sep 17. pii: ERJ-00649-2015. doi: 10.1183/13993003.00649-2015
    PubMed     Text format     Abstract available


    August 2015
  172. RAKOTOSAMIMANANA N, Richard V, Raharimanga V, Gicquel B, et al
    Biomarkers for risk of developing active tuberculosis in contacts of TB patients: a prospective cohort study.
    Eur Respir J. 2015 Aug 6. pii: ERJ-00263-2015. doi: 10.1183/13993003.00263-2015.
    PubMed     Text format     Abstract available



  173. "Contact investigation for tuberculosis: a systematic review and meta-analysis." Gregory J. Fox, Simone E. Barry, Warwick J. Britton and Guy B. Marks. Eur Respir J 2013; 41: 140-156.
    Eur Respir J. 2015;46:578.
    PubMed     Text format    


  174. FALZON D, Raviglione M, Bel EH, Gratziou C, et al
    The role of eHealth and mHealth in tuberculosis and tobacco control: a WHO/ERS consultation.
    Eur Respir J. 2015;46:307-11.
    PubMed     Text format    


  175. NATHAVITHARANA RR, Friedland JS
    A tale of two global emergencies: tuberculosis control efforts can learn from the Ebola outbreak.
    Eur Respir J. 2015;46:293-6.
    PubMed     Text format    


    July 2015
  176. KRIEGER D, Vesenbeckh S, Schonfeld N, Bettermann G, et al
    Mefloquine as a potential drug against multidrug-resistant tuberculosis.
    Eur Respir J. 2015 Jul 23. pii: ERJ-00321-2015. doi: 10.1183/13993003.00321-2015
    PubMed     Text format    


  177. BOLHUIS MS, Tiberi S, Sotgiu G, De Lorenzo S, et al
    Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study.
    Eur Respir J. 2015 Jul 9. pii: ERJ-00606-2015. doi: 10.1183/13993003.00606-2015.
    PubMed     Text format    


    June 2015
  178. KROIDL I, Clowes P, Reither K, Mtafya B, et al
    Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania.
    Eur Respir J. 2015 Jun 25. pii: ERJ-00033-2015. doi: 10.1183/09031936.00003315.
    PubMed     Text format     Abstract available


  179. AMARAL AF, Coton S, Kato B, Tan WC, et al
    Tuberculosis associates with both airflow obstruction and low lung function: BOLD results.
    Eur Respir J. 2015 Jun 25. pii: ERJ-02325-2014. doi: 10.1183/13993003.02325-2014
    PubMed     Text format     Abstract available


  180. MORI T, Burhan E
    Supporting progress towards the post-2015 targets and regional tuberculosis elimination: a statement of intent from the third meeting of the Asian TB Experts Community.
    Eur Respir J. 2015;45:1760-2.
    PubMed     Text format    


    May 2015
  181. VAN DER PAARDT AF, Wilffert B, Akkerman OW, de Lange WC, et al
    Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis.
    Eur Respir J. 2015 May 28. pii: ERJ-01470-2014.
    PubMed     Text format     Abstract available


  182. GILLINI L, Centis R, D'Ambrosio L, Fedele A, et al
    Is Europe ready to reach tuberculosis elimination? An outbreak report from Southern Italy.
    Eur Respir J. 2015 May 28. pii: ERJ-00127-2015.
    PubMed     Text format    


    March 2015
  183. VANDEN DRIESSCHE K, Patel MR, Mbonze N, Tabala M, et al
    Effect of smoking history on outcome of patients diagnosed with TB and HIV.
    Eur Respir J. 2015;45:839-42.
    PubMed     Text format    


    January 2015
  184. TANG S, Yao L, Hao X, Zhang X, et al
    Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.
    Eur Respir J. 2015;45:161-70.
    PubMed     Text format     Abstract available


  185. YU MC, Chen HY, Chien SH, Jou R, et al
    An integrated MDR-TB management programme results in favourable outcomes in northern Taiwan.
    Eur Respir J. 2015;45:272-5.
    PubMed     Text format    


    October 2014
  186. DENKINGER CM, Pai M
    Using cerebrospinal fluid for the diagnosis of tuberculous meningitis with GeneXpert.
    Eur Respir J. 2014;44:1095-6.
    PubMed     Text format    


  187. LUO RF, Gaur RL, Banaei N
    Using cerebrospinal fluid for the diagnosis of tuberculous meningitis with GeneXpert.
    Eur Respir J. 2014;44:1094-5.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: